Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer

BACKGROUND: We previously reported that the addition of erlotinib to gemcitabine and oxaliplatin (GEMOX) resulted in greater antitumor activity and might be a treatment option for patients with biliary tract cancers (BTCs). Molecular subgroup analysis of treatment outcomes in patients who had specim...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Seung Tae Kim, Kee-Taek Jang, Jeeyun Lee, Heung-Moon Jang, Hye-Jin Choi, Hye-Lim Jang, Se Hoon Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Joon Oh Park
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2015-02-01
Colecção:Translational Oncology
Acesso em linha:http://www.sciencedirect.com/science/article/pii/S1936523314001375
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados